273 related articles for article (PubMed ID: 16517052)
1. Optimisation of PDE5 inhibitor therapy in men with erectile dysfunction: converting "non-responders" into "responders".
Eardley I
Eur Urol; 2006 Jul; 50(1):31-3. PubMed ID: 16517052
[No Abstract] [Full Text] [Related]
2. Emergence and success of PDE5 inhibitors as effective therapy for erectile dysfunction.
Manganiello V
Int J Impot Res; 2004 Jun; 16 Suppl 1():S1-3. PubMed ID: 15224126
[No Abstract] [Full Text] [Related]
3. Salvage techniques for phosphodiesterase 5 inhibitor therapy: purposeful but how much?
Burnett AL
Eur Urol; 2006 Jul; 50(1):29-30. PubMed ID: 16567036
[No Abstract] [Full Text] [Related]
4. SAR development of polycyclic guanine derivatives targeted to the discovery of a selective PDE5 inhibitor for treatment of erectile dysfunction.
Pissarnitski DA; Asberom T; Boyle CD; Chackalamannil S; Chintala M; Clader JW; Greenlee WJ; Hu Y; Kurowski S; Myers J; Palamanda J; Stamford AW; Vemulapalli S; Wang Y; Wang P; Wu P; Xu R
Bioorg Med Chem Lett; 2004 Mar; 14(5):1291-4. PubMed ID: 14980684
[TBL] [Abstract][Full Text] [Related]
5. Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
Bi Y; Stoy P; Adam L; He B; Krupinski J; Normandin D; Pongrac R; Seliger L; Watson A; Macor JE
Bioorg Med Chem Lett; 2004 Mar; 14(6):1577-80. PubMed ID: 15006407
[TBL] [Abstract][Full Text] [Related]
6. Cyclic GMP and phosphodiesterase 5 inhibitor therapies: what's on the horizon?
Lincoln TM
Mol Pharmacol; 2004 Jul; 66(1):11-3. PubMed ID: 15213291
[No Abstract] [Full Text] [Related]
7. Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction.
Shabsigh R; Seftel AD; Rosen RC; Porst H; Ahuja S; Deeley MC; Garcia CS; Giuliano F
Urology; 2006 Oct; 68(4):689-96. PubMed ID: 17070333
[No Abstract] [Full Text] [Related]
8. Rationale for androgens and erectile dysfunction in 2006.
Roumeguère T
Eur Urol; 2006 Nov; 50(5):898-900. PubMed ID: 16893603
[No Abstract] [Full Text] [Related]
9. Phosphodiesterase type 5 inhibithors in older males.
Frajese GV; Pozzi F
J Endocrinol Invest; 2005; 28(11 Suppl Proceedings):112-5. PubMed ID: 16760638
[TBL] [Abstract][Full Text] [Related]
10. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy.
Mehrotra N; Gupta M; Kovar A; Meibohm B
Int J Impot Res; 2007; 19(3):253-64. PubMed ID: 16988721
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations.
Rosen RC; Shaw JW
Int J Impot Res; 2006; 18(6):570-1; author reply 572-3. PubMed ID: 17075585
[No Abstract] [Full Text] [Related]
12. Sildenafil in the treatment of erectile dysfunction.
Budenholzer B
N Engl J Med; 1998 Sep; 339(10):701-2. PubMed ID: 9729142
[No Abstract] [Full Text] [Related]
13. The impact of the use of PDE5 inhibitors for erectile dysfunction on the lives of Australian men.
Matic H; McCabe MP
Int J Impot Res; 2007; 19(4):418-23. PubMed ID: 17538638
[TBL] [Abstract][Full Text] [Related]
14. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences.
Greco EA; Spera G; Aversa A
Eur Urol; 2006 Nov; 50(5):940-7. PubMed ID: 16979814
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic strategies for optimizing PDE-5 inhibitor therapy in patients with erectile dysfunction considered difficult or challenging to treat.
de Tejada IS
Int J Impot Res; 2004 Jun; 16 Suppl 1():S40-2. PubMed ID: 15224136
[TBL] [Abstract][Full Text] [Related]
16. This paper continues Professor Adaikan's distinguished involvement in classical pharmacologic research of erectile physiology.
Pickard R
Eur Urol; 2007 Jul; 52(1):259-60. PubMed ID: 17616089
[No Abstract] [Full Text] [Related]
17. [Pharmacotherapy of erectile dysfunction].
Shcheplev PA; Nesterov SN; Kukharkin SA; Abdullaev IA; Sidorov DV
Ter Arkh; 1999; 71(10):76-8. PubMed ID: 10612182
[No Abstract] [Full Text] [Related]
18. Phosphodiesterase type 5 inhibitors' extended duration of response as a variable in the treatment of erectile dysfunction.
Dunn ME; Althof SE; Perelman MA
Int J Impot Res; 2007; 19(2):119-23. PubMed ID: 16738695
[TBL] [Abstract][Full Text] [Related]
19. [How I treat and manage erectile dysfunction in diabetics].
Buvat J
Journ Annu Diabetol Hotel Dieu; 2006; ():185-203. PubMed ID: 17051861
[No Abstract] [Full Text] [Related]
20. The multinational Men's Attitudes to Life Events and Sexuality (MALES) Study Phase II: understanding PDE5 inhibitor treatment seeking patterns, among men with erectile dysfunction.
Fisher WA; Rosen RC; Eardley I; Niederberger C; Nadel A; Kaufman J; Sand M
J Sex Med; 2004 Sep; 1(2):150-60. PubMed ID: 16422969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
